hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06284694 id: REB23-0120 briefTitle: Treatment of Neuropathic Pain Following Spinal Cord Injury - a rTMS Approach overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-06-30 date: 2025-06-30 date: 2024-02-29 date: 2024-02-29 name: University of Calgary class: OTHER briefSummary: This study aims to determine if repetitive transcranial magnetic stimulation (rTMS) can improve pain symptomology in adults with neuropathic pain (NP) following a spinal cord injury (SCI). conditions: Neuropathic Pain studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: All participants will receive active rTMS treatment. primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Repetitive Transcranial Magnetic Stimulation (rTMS) measure: International Spinal Cord Injury Pain Basic Data Set (ISCIPBDS) v3.0 measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Scale Neuropathic Pain Quality 5a measure: Quality of Life Index Spinal Cord Injury version (QLI-SCI) measure: Pain Catastrophizing Scale (PCS) measure: World Health Organization Disability Assessment Schedule (WHODAS) 2.0 measure: Generalized Anxiety Disorder scale-7 (GAD-7) measure: Patient Health Questionnaire-9 (PHQ-9) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Foothills Medical Centre city: Calgary state: Alberta zip: T2N 2T9 country: Canada lat: 51.05011 lon: -114.08529 hasResults: False
nctId: NCT06284668 id: GWang027 briefTitle: Esketamine vs Remimazolam for Postoperative Sleep Disturbance and Anxiety overallStatus: RECRUITING date: 2024-03-04 date: 2024-06-20 date: 2024-07-10 date: 2024-02-29 date: 2024-03-05 name: Tianjin Medical University General Hospital class: OTHER briefSummary: To explore and compare the effects of esketamine and remimazolam on postoperative sleep disturbance in patients undergoing oocyte retrieval conditions: Sleep Disturbance studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 300 type: ESTIMATED name: normal Saline name: Esketamine name: Remimazolam measure: The incidence of postoperative sleep disturbance on the first night after surgery measure: The incidence of sleep disturbance one day before surgery measure: The incidence of postoperative sleep disturbance on the second and third postoperative nights measure: Postoperative anxiety measure: Postoperative depression measure: Pain Score (NRS) measure: Mean intraoperative blood pressure measure: Oxygen saturation measure: Somatokinetic reaction measure: Operation time measure: Duration of anesthesia measure: Time to walking down measure: Adverse event sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Tianjin Medical University General Hospital status: RECRUITING city: Tianjin zip: 300052 country: China name: Guolin Wang role: CONTACT phone: +8618604755166 email: wangguolinghad@hotmail.com lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06284655 id: 635362 a briefTitle: The Effect of a Brief Educational Intervention for Adults With ADHD overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2027-01 date: 2030-12 date: 2024-02-29 date: 2024-02-29 name: St. Olavs Hospital class: OTHER name: Norwegian University of Science and Technology briefSummary: This RCT-study proposes the evaluation of an intensive educational intervention tailored for adults with Attention Deficit Hyperactivity Disorder (ADHD) in community mental health centers (CMHCs). Given the prevalent challenges of prolonged waiting lists and low patient engagement in CMHCs, the research seeks to assess the efficacy of this intervention in enhancing patient engagement, self-efficacy, satisfaction with the information and overall health outcomes. The intervention, developed collaboratively with user representatives, combines a brief group-based educational sessions with standard clinical care. The primary hypotheses posit that this approach will lead to increased patient satisfaction with the treatment, patient self-efficacy, and activation compared to conventional treatment. Additionally, it aims to improve patients' satisfaction with information received. The study will employ a ITT analysis to assess the intervention's effects against usual treatment practices in outpatient settings. The anticipated outcome is a significant improvement in level of patient satisfaction, level of self-efficacy and level of satisfaction with the received information for patients with ADHD, potentially informing clinical practices and optimizing care for adults with ADHD. conditions: ADHD studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel two-arms randomized control trial primaryPurpose: OTHER masking: SINGLE maskingDescription: Blinded statistician whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: group-based combined with innovative technology education name: Standard treatment measure: Change in client satisfaction using CSQ measure: Change in general self-efficacy using GSE-6 measure: Change in satisfaction with the information measure: Knowledge and treatment preferences measure: Change in patient activation using PAM measure: Change in ADHD-related symptoms using ASRS measure: Change in ADHD-related symptoms using SCL-9 measure: Change in depression and anxiety symptoms using PHQ-4 measure: Change in patient enablement using PEN-13 measure: Change in stress level using PSS-4 measure: Change in level of functioning using WSAS measure: Change in ADHD Quality of life using AAQoL measure: Change in Health-related Quality of life using EQ-5D-5L measure: Cost measure: Health care usage sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St Olav's Hospital city: Trondheim country: Norway name: Mariela Loreto Lara-Cabrera, PhD role: CONTACT email: mariela.lara@ntnu.no lat: 63.43049 lon: 10.39506 hasResults: False
nctId: NCT06284642 id: LD-ITUK-2024-001 briefTitle: Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK) overallStatus: RECRUITING date: 2024-03-28 date: 2026-01-30 date: 2026-06-30 date: 2024-02-29 date: 2024-04-15 name: Second Affiliated Hospital of Nanchang University class: OTHER name: Changhai Hospital briefSummary: The LD-ITUK is a multicenter, prospective, randomized, double-blind, blind endpoint, placebo-control design trial. All eligible patients with the diagnosis of severe aSAH will be randomly assigned to the treatment group or the placebo group. Patients in the treatment group will receive standard treatment with the addition of lumbar drainage combined with intrathecal urokinase injection started within 24 hours after aneurysm treatment with 30000 IU urokinase, once a day for 3 consecutive days. Patients in the control group will receive standard treatment with the addition of lumbar drainage combined with intrathecal placebo (0.9%NaCl) injection. The primary outcome measure is favorable functional outcome, defined as a score of 0 to 2 on the modified Rankin Scale (mRS), at 6 months after aneurysmal SAH. Primary outcome will be determined by a member of the Independent Committee on Terminal events. conditions: Aneurysmal Subarachnoid Hemorrhage studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 424 type: ESTIMATED name: Urokinase name: Placebo measure: Modified Rankin Scale (mRS) measure: Modified Rankin Scale (mRS) measure: Relative Modified Rankin Scale (mRS) measure: Modified Rankin Scale (mRS) distribution measure: Glasgow Outcome Scale (GOS） measure: Questionnaire EuroQol Five Dimensions Questionnaire (EQ-5D) measure: Barthel Index for Activities of Daily Living (BI) measure: Total hospitalized time measure: Total hospitalized costs measure: Cerebral vasospasm (CV) measure: Delayed cerebral ischemia (DCI) measure: Death measure: Hydrocephalus measure: Rebleeding measure: Subarachnoid hemorrhage volume clearance measure: Correlationship between cerebralspinal fluid pressure with subarachnoid hemorrhage volume measure: Correlationship between clinical grades and subarachnoid hemorrhage volume sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Second Affiliated Hospital of Nanchang University status: RECRUITING city: Nanchang state: Jiangxi zip: 330006 country: China name: Xingen Zhu, MS role: CONTACT email: zxg2008vip@163.com lat: 28.68396 lon: 115.85306 hasResults: False
nctId: NCT06284629 id: PD-DigiCare briefTitle: Enhancing Referral Decision-making for Advanced Treatment in Parkinson's Disease Through Objective Measurements and Patient Reported Outcomes. acronym: PD-DigiCare overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2026-09-01 date: 2026-09-01 date: 2024-02-29 date: 2024-04-22 name: Rigshospitalet, Denmark class: OTHER name: Odense University Hospital name: Zealand University Hospital briefSummary: The overall aim of the trial is to compare the efficacy of using wearables and patient-reported outcome measures versus standard care in enhancing the timeliness of referrals to advanced monitoring of treatments for people with Parkinson's Disease. conditions: Parkinson Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE maskingDescription: Participants and physicians will be blinded to device and app data in the control group. Blinding of the group allocation is not possible due to the investigated device. count: 90 type: ESTIMATED name: Neptune name: Standard clinical care measure: Differences between groups in algorithm-based motor symptom burden (time spent in the ON state without dyskinesias) at referral to evaluation for advanced treatment. measure: Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention. measure: Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention. measure: Changes in type of, frequency and dose of medication (calculated Levodopa Equivalent Dose, LED, by use of Tomlinson's scale) measure: Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention. measure: Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention. measure: Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention. measure: Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rigshospitalet Glostrup city: Glostrup zip: 2600 country: Denmark name: Nikolaj la Cour Karottki, MD role: CONTACT phone: 40432773 email: nikolaj.folke.la.cour.karottki.01@regionh.dk lat: 55.6666 lon: 12.40377 facility: Odense University Hospital city: Odense country: Denmark name: Morten Blaabjerg, MD role: CONTACT lat: 55.39594 lon: 10.38831 facility: Zealand University Hospital, Roskilde city: Roskilde country: Denmark name: Helle Thagesen, MD role: CONTACT lat: 55.64152 lon: 12.08035 hasResults: False
nctId: NCT06284616 id: K2019-0392 briefTitle: JASP-1 for Children Recently Diagnosed and Their Parents acronym: JASP-1 overallStatus: COMPLETED date: 2019-08-15 date: 2023-04-15 date: 2023-12-31 date: 2024-02-29 date: 2024-03-06 name: Region Stockholm class: OTHER_GOV briefSummary: To implement and evaluate a patient-and family-centered Juvenile Arthritis Support Program during one year (JASP-1) for children recently diagnosed with JIA and their parents and after 12 months compare satistaction with care and health outcomes with a control group receiving standard care. conditions: JIA conditions: Support Program conditions: Patient Satisfaction conditions: Patient Outcome Assessment studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study is a non-randomized intervention study with 2 groups receiving either a Support program (JASP-1) or standard care primaryPurpose: SUPPORTIVE_CARE masking: NONE maskingDescription: All patient receiving a JIA diagnose was offered to participate in JASP-1. The controls had received diagnose before the start of the study. count: 82 type: ACTUAL name: JASP-1 measure: Rate of Patient Reported Experienced Measures (PREM) measure: Rate of Overall perceived health measure: Rate of Child Health Activity Questionnaire (CHAQ) measure: Number of active joints sex: ALL minimumAge: 1 Year maximumAge: 16 Years stdAges: CHILD facility: Astrid Lindgren Children´s Hospital city: Stockholm state: Region Stockholm zip: 17176 country: Sweden lat: 59.33258 lon: 18.0649 hasResults: False
nctId: NCT06284603 id: AWF_LA_HBOT briefTitle: Effectiveness of Hyperbaric Oxygen Therapy in Adults overallStatus: COMPLETED date: 2022-03-01 date: 2023-12-20 date: 2023-12-20 date: 2024-02-29 date: 2024-02-29 name: Poznan University of Physical Education class: OTHER briefSummary: The goal of this controlled, experimental study is to learn about the effects of 10 sessions of hyperbaric oxygen therapy on physical performance, vascular circulation, biochemical parameters, and composition of the intestinal microbiota in young healthy men depending on the frequency of single treatments.
Participants are exposed to hyperoxia under hyperbaric conditions or form a control group with no treatment. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Two study groups (dependent on frequency of HBOT treatments) and control group primaryPurpose: TREATMENT masking: NONE count: 80 type: ACTUAL name: Hyperbaric Oxygen Therapy - HBOT measure: Volume of oxygen and carbon dioxide measure: Heart rate measure: Vascular circulation measures measure: Body composition (body mass, fat mass, lean body mass, muscle mass) measure: Inflammatory cytokine profile measure: Oxidative stress indicators measure: F2-Isoprostanes (F2-IsoP) measure: Brain-derived neurotrophic factor concentration (BDNF) measure: Nicotinamide (NAD) metabolites measure: Gut microbiome and metabolome measure: Indicators of intestinal inflammation (fecal calprotectin, claudin, occludin, zonulin, sIgA) measure: endothelial nitric oxide synthase (eNOS) measure: Vascular endothelial growth factor (VEGF) measure: Hypoxia inducible factor-1 (HIF-1alfa) sex: MALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Poznan University of Physical Education city: Poznan state: Wielkopolska zip: 61-871 country: Poland lat: 52.40692 lon: 16.92993 hasResults: False
nctId: NCT06284590 id: PH-ICKPD1-02/21 id: MK-3475-F20 type: OTHER domain: Merck Sharp & Dohme LLC id: KEYNOTE-F20 type: OTHER domain: missing briefTitle: Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients acronym: INTACT/MeRCI overallStatus: ACTIVE_NOT_RECRUITING date: 2023-12-19 date: 2028-07 date: 2028-07 date: 2024-02-29 date: 2024-04-08 name: Philogen S.p.A. class: INDUSTRY name: Merck Sharp & Dohme LLC briefSummary: The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for anti-PD1 refractory unresectable stage III-IV melanoma. conditions: Melanoma Stage III conditions: Melanoma Stage IV studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 162 patients. Patients enrolled will be randomized in a 1:1:1 ratio. i) systemic pembrolizumab in combination with intralesional L19IL2 (Arm 1): 54 patients.
ii) systemic pembrolizumab in combination with intralesional L19TNF (Arm 2): 54 patients iii) systemic pembrolizumab in combination with intralesional L19IL2/L19TNF (Arm 3): 54 patients primaryPurpose: TREATMENT masking: NONE count: 162 type: ESTIMATED name: L19IL2 name: L19TNF name: L19IL2/L19TNF name: KEYTRUDA® measure: Confirmed Objective Response Rate (ORR) measure: Best overall response (BOR) measure: Duration of Response (DoR) measure: Pathological response measure: Confirmed ORR measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Serious Adverse Event (SAEs) measure: Drug-Induced Liver Injury (DILI) measure: Number of patients with Adverse Events of Special Interest (AESI) measure: Number of patients with Immune-Related Adverse Events (IRAEs) measure: Number of participants with abnormal hematology laboratory tests results measure: Number of participants with abnormal hematology laboratory tests results measure: Number of participants with abnormal hematology laboratory tests results measure: Number of participants with abnormal hematology laboratory tests results measure: Number of participants with abnormal serum chemistry laboratory tests results measure: Number of participants with abnormal serum chemistry laboratory tests results measure: Number of participants with abnormal serum chemistry laboratory tests results measure: Number of participants with abnormal serum chemistry laboratory tests results measure: Number of participants with abnormal serum chemistry laboratory tests results measure: Number of participants with abnormal coagulation laboratory tests results measure: Number of participants with abnormal body temperature measure: Number of participants with abnormal blood pressure measure: Number of participants with abnormal Electrocardiogram (ECG) readings measure: Number of participants with abnormal Echocardiogram (ECHO) readings measure: Number of participants with abnormal physical examination results measure: Concomitant medication usage measure: Assessment of the formation of human anti-fusion protein antibodies (HAFA) against L19IL2 and L19TNF sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Memorial Sloan Kettering Cancer Center city: New York state: New York zip: 10065 country: United States lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06284577 id: 677186 briefTitle: Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis overallStatus: RECRUITING date: 2024-01-02 date: 2027-06-01 date: 2027-07-01 date: 2024-02-29 date: 2024-02-29 name: Oslo University Hospital class: OTHER briefSummary: The aim of the present study is to investigate the effect of probiotic supplementation on GI related quality of life, through a randomised placebo-controlled clinical trial. Moreover, the invetigators wish to study CF microbiota and intestinal inflammation in the setting of probiotic supplementation and newly started treatment with a highly effective CF-specific treatment, elexacaftor-tezacaftor-ivacaftor (ETI). The proposed project has the potential to increase QoL and decrease GI morbidity in children with CF. If successful, the results of this study can contribute to alter the care of CF patients by including supplementation of probiotics in routine CF care. Morever, the study can provide much needed insights to GI microbiota and inflammation in pediatric CF patients. conditions: Cystic Fibrosis in Children studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 40 type: ESTIMATED name: Multistrain Probiotic name: Placebo - maltodextrin measure: Changes in GI related QoL using the questionnaire PedsQL GI measure: Changes in microbiota measure: Changes in intestinal inflammation sex: ALL minimumAge: 2 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Oslo University Hospital status: RECRUITING city: Oslo country: Norway name: Magnhild P Kolsgaard, PhD role: CONTACT phone: 0047 41514045 email: uxpoma@ous-hf.no name: Camilla Styffe Sæland, Master role: CONTACT phone: 004793257798 email: casael@ous-hf.no name: Magnhild P Kolsgaard, PhD role: PRINCIPAL_INVESTIGATOR name: Camilla Styffe Sæland, Master role: SUB_INVESTIGATOR name: Linh Dieu Ngo, Master role: SUB_INVESTIGATOR lat: 59.91273 lon: 10.74609 hasResults: False
nctId: NCT06284564 id: 2023-0538 id: NCI-2024-03604 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) overallStatus: NOT_YET_RECRUITING date: 2024-09-30 date: 2024-10-01 date: 2026-10-01 date: 2024-02-29 date: 2024-04-26 name: M.D. Anderson Cancer Center class: OTHER name: Bristol-Myers Squibb name: Cancer Prevention Research Institute of Texas name: United States Department of Defense briefSummary: To learn if evolocumab and nivolumab can control metastatic and refractory renal cell carcinoma. The safety of this drug combination will also be studied. conditions: Metastatic Renal Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Evolocumab name: Nivolumab measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Eric Jonasch, MD role: CONTACT phone: 713-563-7232 email: ejonasch@mdanderson.org name: Eric Jonasch, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06284551 id: 202111069RINB briefTitle: The Relationship Between Internet-use Behavior and Mental Health in Youth overallStatus: ENROLLING_BY_INVITATION date: 2022-02-08 date: 2024-02-15 date: 2025-01-27 date: 2024-02-29 date: 2024-02-29 name: National Taiwan University Hospital class: OTHER briefSummary: Introduction: WHO defines youth as 15-24 years age group. At this stage, the brain is still under development, with high impulsiveness, being fond of stimulation and yearning for peer life. Compared with traditional interpersonal interaction, modern youths use the Internet as a main interpersonal interaction platform and conduct lots of leisure activities on the Internet. Poor cognitive emotion regulation strategies and personal traits may extend to new types of mental health issues; and are associated with depression, anxiety, suicidal/self-injurious behaviors, and cyberbullying.
Method: This cross-sectional study recruits cases of youths from 15 to 24 years old and collects data through questionnaires survey. In addition to collection of basic data, Internet using habits, and medical history, self-rated questionnaires include Suicide/Self-Injury Ideation Questionnaire, The Beck Depression Inventory 2nd Edition, Multidimensional Anxiety Scale for Children-Taiwan version, Cognitive Emotion Regulation Questionnaire, Cyberbullying Questionnaire, and Internet Gaming Disorder Scale-Short Form. conditions: Mental Health Issue studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 50 type: ESTIMATED measure: Cyberbullying Questionnaire measure: Beck's Depression Inventory (BDI-II) sex: ALL minimumAge: 15 Years maximumAge: 24 Years stdAges: CHILD stdAges: ADULT facility: National Taiwan University Hospital city: Taipei country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False